N/A
Manufactured by Total Resources International
12,389 FDA adverse event reports analyzed
Last updated: 2026-04-15
NEOMYCIN SULFATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Total Resources International. The most commonly reported adverse reactions for NEOMYCIN SULFATE include DRUG INEFFECTIVE, DRUG HYPERSENSITIVITY, PAIN, NAUSEA, DYSPNOEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for NEOMYCIN SULFATE.
Out of 2,669 classified reports for NEOMYCIN SULFATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 12,389 FDA FAERS reports that mention NEOMYCIN SULFATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, DRUG HYPERSENSITIVITY, PAIN, NAUSEA, DYSPNOEA, MALAISE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Total Resources International in connection with NEOMYCIN SULFATE. Always verify the specific product and NDC with your pharmacist.